公开(公告)号：EP2470526B1

公开(公告)日：2014-05-28

申请号：EP10748211.9

申请日：2010-08-27

申请人： IRM LLC ,  Novartis AG

发明人： HUANG, Shenlin ,  JIN, Xianming ,  LIU, Zuosheng ,  POON, Daniel ,  TELLEW, John ,  WAN, Yongqin ,  WANG, Xing ,  XIE, Yongping

IPC分类号： C07D401/14 ,  C07D403/04 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D403/04 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  A61K2300/00

摘要： The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：EP2170867A1

公开(公告)日：2010-04-07

申请号：EP08770592.7

申请日：2008-06-10

申请人： IRM LLC

发明人： HUANG, Shenlin ,  LIU, Zuosheng ,  ALBAUGH, Pamela, A. ,  WANG, Xing ,  PAN, Shifeng ,  XIE, Yongping ,  ZHANG, Guobao

IPC分类号： C07D401/14 ,  C07D403/04

CPC分类号： C07D401/14 ,  C07D403/04

摘要： The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of Alk, Abl, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, CSK, C-Src, EphB1, EphB2, EphB4, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRα, PDGFRβ, PKCα, SAPK2α, Src, SIK, Syk, Tie2 and TrkB kinases.

公开(公告)号：EP2470526A1

公开(公告)日：2012-07-04

申请号：EP10748211.9

申请日：2010-08-27

申请人： IRM LLC ,  Novartis AG

发明人： HUANG, Shenlin ,  JIN, Xianming ,  LIU, Zuosheng ,  POON, Daniel ,  TELLEW, John ,  WAN, Yongqin ,  WANG, Xing ,  XIE, Yongping

IPC分类号： C07D401/14 ,  C07D403/04 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D403/04 ,  A61K9/0053 ,  A61K31/4184 ,  A61K31/506 ,  A61K45/06 ,  C07D401/14 ,  C07D405/14 ,  A61K2300/00

摘要： The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

摘要翻译： 本发明提供了一类新的式1化合物，包含这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调的激酶活性有关的疾病或病症，特别是涉及异常活化B-Raf的疾病或病症的方法 。

公开(公告)号：EP2531498A1

公开(公告)日：2012-12-12

申请号：EP11703560.0

申请日：2011-02-04

申请人： IRM LLC ,  Novartis AG

发明人： TELLEW, John E. ,  PAN, Shifeng ,  WAN, Yongqin ,  XIE, Yongping ,  WANG, Xing ,  WANG, Xia ,  HUANG, Shenlin ,  LIU, Zuosheng ,  ZHANG, Qiong

IPC分类号： C07D401/14 ,  C07D471/04 ,  A61K31/4353 ,  A61P35/00

CPC分类号： C07D471/04 ,  A61K31/444 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  C07D401/14

摘要： The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R
2 , R
3 , R
4 and R
5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：EP2057146A1

公开(公告)日：2009-05-13

申请号：EP07814982.0

申请日：2007-09-24

申请人： IRM LLC ,  NOVARTIS AG

发明人： ALBAUGH, Pamela ,  CHOPIUK, Gregory S. ,  DING, Qiang ,  HUANG, Shenlin ,  LIU, Zuosheng ,  PAN, Shifeng ,  REN, Pingda ,  WANG, Xia ,  WANG, Xing ,  XIE, Yongping ,  ZHANG, Chengzhi ,  ZHANG, Qiong ,  ZHANG, Guobao ,  POON, Daniel ,  RENHOWE, Paul ,  SENDZIK, Martin

IPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.

摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，ARG，BCR异常活化的疾病或病症 -Abl，BRK，EphB，Fms，Fyn，KDR，c-Kit，LCK，PDGF-R，b-Raf，c-Raf，SAPK2，Src，Tie2和TrkB激酶。

公开(公告)号：EP2102190A1

公开(公告)日：2009-09-23

申请号：EP07853354.4

申请日：2007-12-11

申请人： IRM LLC

发明人： MI, Yuan ,  ALBAUGH, Pamela ,  FAN, Yi ,  CHOI, Ha-Soon ,  LIU, Zuosheng ,  HUANG, Shenlin

IPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  A61K31/404 ,  A61P35/00

CPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14

摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly TrkA, TrkB, TrkC, PDGFR and c-kit.